Journal Mobile Options
Table of Contents
Vol. 86, No. 3, 2013
Issue release date: September 2013
Respiration 2013;86:190-200
(DOI:10.1159/000341175)

Usefulness of the LCOPD, CAFS and CASIS Scales in Understanding the Impact of COPD on Patients

Miravitlles M. · Iriberri M. · Barrueco M. · Lleonart M. · Villarrubia E. · Galera J.
aInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Ciber de Enfermedades Respiratorias (CIBERES), bNovartis Farmacéutica S.A., and cHealth Outcomes Research Department, 3D Health Research, Barcelona, dHospital de Cruces, Barakaldo, and eHospital Universitario de Salamanca, Salamanca, Spain

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: The Living with COPD (LCOPD), COPD and Asthma Fatigue Scale (CAFS), and COPD and Asthma Sleep Impact Scale (CASIS) are instruments developed to assess the overall impact of chronic obstructive pulmonary disease (COPD) on daily life, fatigue, and sleep impairment, respectively. Objectives: To assess the usefulness of these instruments and to identify factors associated with the concepts they measure. Method: The questionnaires were administered to patients with moderate to severe COPD. Descriptive analyses of sociodemographic and clinical data were performed, and bivariate and multivariate analyses were used to identify factors associated with the overall impact of COPD on patients' lives, fatigue, and sleep impairment. Results: A total of 408 patients was included (mostly males, 91.2%), with an average age of 68 years (SD = 9.3). Statistically significant differences were observed in the scores of the three questionnaires with regard to level of education, presence of chronic cough or expectoration, level of dyspnea, number of exacerbations, physical activity level, presence of depression and anxiety, and number of treatments indicated for COPD. The LCOPD and CAFS questionnaires also discriminated between different levels of airflow obstruction and, in the case of CAFS, age and gender. Linear regression showed that level of dyspnea, physical activity, and presence of anxiety were significantly related to the LCOPD, CAFS and CASIS scores. The presence of depression was significant in the LCOPD and CAFS questionnaires and chronic cough was significant in the CAFS questionnaire. Conclusions: The LCOPD, CAFS, and CASIS instruments are valid and useful in understanding the overall impact of COPD on daily life, fatigue, and sleep impairment in patients with moderate to severe COPD.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Chapman KR, Mannino DM, Soriano JB, Vermeire PA, Buist AS, Thun MJ, et al: Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J 2006;27:188-207.
  2. Ferrer M, Alonso J, Morera J, Marrades RM, Khalaf A, Aguar C, et al: Chronic obstructive pulmonary disease stage and health-related quality of life. Ann Intern Med 1997;127:1072-1079.
  3. Miravitlles M, Anzueto A, Legnani D, Forstmeier L, Fargel M: Patient's perception of exacerbations of COPD - the PERCEIVE study. Respir Med 2007;101:453-460.
  4. Alvarez-Gutiérrez FJ, Miravitlles M, Calle M, Gobartt E, López F, Martín A, et al: Impact of chronic obstructive pulmonary disease on activities of daily living: results of the EIME multicenter study. Arch Bronconeumol 2007;43:64-72.

    External Resources

  5. Peters JB, Daudey L, Heijdra YF, Molema J, Dekhuijzen PN, Vercoulen JH: Development of a battery of instruments for detailed measurement of health status in patients with COPD in routine care: the Nijmegen Clinical Screening Instrument. Qual Life Res 2009;18:901-912.
  6. Miravitlles M, Alvarez-Sala JL, Lamarca R, Ferrer M, Masa F, Verea H, et al: Treatment and quality of life in patients with chronic obstructive pulmonary disease. Qual Life Res 2002;11:329-338.
  7. Jones PW, Quirk FH, Baveytock CM, Littlejohns P: A self-complete measure of health status for chronic airflow limitation: the St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992;145:1321-1327.

    External Resources

  8. Badia X, Roset M, Montserrat S, Herdman M, Segura A: La versión española del EUROQoL: descripción y aplicaciones. Med Clin 1999;112(suppl 1):79-85.

    External Resources

  9. Simon-Pickard A, Wilke C, Jung E, Patel S, Stavem K, Lee TA: Use of a preference-based measure of health (EQ-5D) in COPD and asthma. Respir Med 2008;102:519-536.
  10. Engström CP, Persson LO, Larsson S, Sullivan M: Health-related quality of life in COPD: why both disease-specific and generic measures should be used. Eur Respir J 2001;18:69-76.
  11. Hill K, Geist R, Goldstein RS, Lacasse Y: Anxiety and depression in end-stage COPD. Eur Respir J 2008;31:667-677.
  12. Eiser N, Harte R, Spiros K, Phillips C, Isaac MT: Effect of treating depression on quality-of-life and exercise tolerance in severe COPD. COPD 2005;2:233-241.
  13. Herrero MJ, Blanch J, Peri JM, De Pablo J, Pintor L, Bulbena A: A validation study of the Hospital Anxiety and Depression scale (HADS) in a Spanish population. Gen Hosp Psychiatry 2003;25:277-283.
  14. Hanania NA, Müllerova H, Locantore NW, Vestbo J, Watkins ML, Wouters EF, Rennard SI, Sharafkhaneh A, Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study investigators: Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am J Respir Crit Care Med 2011;183:604-611.
  15. Garcia-Aymerich J, Félez MA, Escarrabill J, Marrades RM, Morera J, Elosua R, et al: Physical activity and its determinants in severe chronic obstructive pulmonary disease. Med Sci Sports Exerc 2004;36:1667-1673.
  16. Eisner MD, Iribarren C, Blanc PD, Yelin EH, Ackerson L, Byl N, et al: Development of disability in chronic obstructive pulmonary disease: beyond lung function. Thorax 2011;66:108-114.
  17. Garrod R, Bestall JC, Paul EA, Wedzicha JA, Jones PW: Development and validation of a standardized measure of activity of daily living in patients with severe COPD: the London Chest Activity of Daily Living scale (LCADL). Respir Med 2000;94:589-596.
  18. Vilaró J, Gimeno E, Sánchez Férez N, Hernando C, Díaz I, Ferrerc M, et al: Daily living activity in chronic obstructive pulmonary disease: validation of the Spanish version and comparative analysis of 2 questionnaires (in Spanish). Med Clin (Barc) 2007;129:326-332.
  19. López-Campos JL: Importance of fatigue, sleep quality and mood in patients with chronic obstructive pulmonary disease and the need for measurement instruments. Arch Bronconeumol 2009;45(suppl 5):2-6.
  20. Breslin E, van der Schans C, Breukink S, Meek P, Mercer K, Volz W, et al: Perception of fatigue and quality of life in patients with COPD. Chest 1998;114:958-964.
  21. Bhullar S, Phillips B: Sleep in COPD patients. COPD 2005;2:355-361.
  22. Revicki DA, Meads DM, McKenna SP, Gale R, Glendenning GA, Pokrzywinski RF: COPD and Asthma Fatigue Scale (CAFS): development and psychometric assessment. Health Outcomes Res Med 2010;1:e5-e16.
  23. Pokrzywinski RF, Meads DM, McKenna SP, Glendenning GA, Revicki DA: Development and psychometric assessment of the COPD and Asthma Sleep Impact Scale (CASIS). Health Qual Life Outcomes 2009;7:98.
  24. McKenna SP, Meads DM, Doward LC, Twiss J, Pokrzywinski R, Revicki D, Hunter CJ, Glendenning GA: Development and validation of the living with chronic obstructive pulmonary disease questionnaire. Qual Life Res 2011;20:1043-1052.
  25. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA: Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54:581-586.
  26. McKenna SP, Twiss J, Crawford SR, Oprandi NC, Tammaru M, Miravitlles M: Adapting the Living with Chronic Obstructive Pulmonary Disease (LCOPD) for use in Southern European (Italian and Spanish) and Eastern European (Russian) cultures. J Clin Epidemiol 2012;65:906-914.
  27. Galera J, Lahoz R, Lleonart M, Miravitlles M: Validation of the Spanish version of the COPD and asthma fatigue scale (CAFS) questionnaire (PRS42, October 2009, ISPOR 12th Annual European Congress, Paris, France). http://www.ispor.org/research_study_digest/research_index.asp.
  28. Lahoz R, Galera J, Lleonart M, Miravitlles M: Validation of the Spanish version of the COPD and asthma sleep impact scale (CASIS) questionnaire (PRS39, October 2009, ISPOR 12th Annual European Congress, Paris, France). http://www.ispor.org/research_study_digest/research_index.asp.
  29. Herrero MJ, Blanch J, Peri JM, De Pablo J, Pintor L, Bulbena A: A validation study of the Hospital Anxiety and Depression Scale (HADS) in a Spanish population. Gen Hosp Psychiatry 2003;25:277-283.
  30. Zigmond AS, Snaith RP: The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983;67:361-370.
  31. Miravitlles M: Cough and sputum production as risk factors for poor outcomes in patients with COPD. Respir Med 2011;105:1118-1128.
  32. Blanco-Aparicio M, Vázquez-Rodríguez I, Verea-Hernando H: Cultural adaptation into Spanish of the Airways Questionnaire 20, a short health-related quality of life questionnaire for the clinical evaluation of asthma and chronic obstructive pulmonary disease. Arch Bronconeumol 2009;45:24-29.
  33. Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA: Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-1422.
  34. Miravitlles M, Ferrer M, Pont A, Zalacain R, Alvarez-Sala JL, Masa F, et al: Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 2004;59:387-395.
  35. Miravitlles M, Naberan K, Cantoni J, Azpeitia A: Socioeconomic status and health-related quality of life of patients with chronic obstructive pulmonary disease. Respiration 2011;82:402-408.
  36. Esteban C, Quintana JM, Aburto M, Moraza J, Egurrola M, Pérez-Izquierdo J, et al: Impact of changes in physical activity on health-related quality of life among patients with COPD. Eur Respir J 2010;36:292-300.
  37. Miravitlles M, Llor C, de Castellar R, Izquierdo I, Baró E, Donado E: Validation of the COPD severity score for its use in primary care: the NEREA study. Eur Respir J 2009;33:519-527.
  38. Ng TP, Niti M, Tan WC, Cao Z, Ong KC, Eng P: Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch Intern Med 2007;167:60-67.
  39. Marín Royo M, Pellicer Císcar C, González Villaescusa C, Bueso Fabra MJ, Aguar Benito C, Andreu Rodríguez AL, et al: Physical activity and its relationship with the state of health of stable COPD patients. Arch Bronconeumol 2011;47:335-342.
  40. Breukink SO, Strijbos JH, Koorn M, Koëter GH, Breslin EH, van der Schans CP: Relationship between subjective fatigue and psychological variables in patients with chronic obstructive pulmonary disease. Respir Med 1998;92:676-682.
  41. Watz H, Waschki B, Boehme C, Claussen M, Meyer T, Magnussen H: Extrapulmonary effects of chronic obstructive pulmonary disease on physical activity: a cross-sectional study. Am J Respir Crit Care Med 2008;177:743-751.
  42. Matkovic Z, Huerta A, Soler N, Domingo R, Gabarrús A, Torres A, Miravitlles M: Predictors of adverse outcome in patients hospitalised for exacerbation of COPD. Respiration 2012;84:17-26.
  43. Al-shair K, Kolsum U, Berry P, Smith J, Caress A, Singh D, et al: Development, dimensions, reliability and validity of the novel Manchester COPD fatigue scale. Thorax 2009;64:950-955.
  44. Heijdra YF, Pinto-Plata VM, Kenney LA, Rassulo J, Celli BR: Cough and phlegm are important predictors of health status in smokers without COPD. Chest 2002;121:1427-1433.
  45. Miravitlles M, Molina J, Naberan K, Cots JM, Ros F, Llor C: Factors determining the quality of life of patients with COPD in primary care. Ther Adv Respir Dis 2007;1:85-92.
  46. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ: The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193-213.
  47. Scharf SM, Maimon N, Simon-Tuval T, Bernhard-Scharf BJ, Reuveni H, Tarasiuk A: Sleep quality predicts quality of life in chronic obstructive pulmonary disease. Int J Chron Obst Pulm Dis 2011;6:1-12.
  48. Lewis CA, Fergusson W, Eaton T, Zeng I, Kolbe J: Isolated nocturnal desaturation in COPD: prevalence and impact on quality of life and sleep. Thorax 2009;64:133-138.
  49. Frei A, Svarin A, Steurer-Stey C, Puhan MA: Self-efficacy instruments for patients with chronic diseases suffer from methodological limitations - a systematic review. Health Qual Life Outcomes 2009:26;7:86.
  50. Jones PW, Price D, van der Molen T: Role of clinical questionnaires in optimizing everyday care of chronic obstructive pulmonary disease. Int J Chron Obst Pulm Dis 2011;6:289-296.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50